An interaction study in healthy volunteers reported an increase in repaglinide AUC to 2.3 times that of the control, and an increase in Cmax of 62%.

Deferasirox is a weak inhibitor of CYP2C8 and CYP3A4 and may enhance the hypoglycaemic effect of repaglinide. The two drugs should not be used concomitantly and modifications to the package insert of repaglinide have been submitted to the clinical unit of the MCC.